Ceapro Inc V.CZO

This is the drug Dr. Tardif has been investigating:

[prophetoffactz]

Dr. Suzan GharaibehDr. Suzan Gharaibeh• 3rd+• 3rd+American Board Endocrinology, Diabetes & Metabolism. Consultant Endocrinologist. Talented Diabetologist. Obesity Expert. Passionate about Diabetes, Obesity, Cardiometabolic Health, Weight Management, and Thyroid.American Board Endocrinology, Diabetes & Metabolism. Consultant Endocrinologist. Talented Diabetologist. Obesity Expert. Passionate about Diabetes, Obesity, Cardiometabolic Health, Weight Management, and Thyroid.

4d • Edited • 4d • Edited •

Follow

 

The FDA has approved the anti-inflammatory drug colchicine 0.5 mg daily (Lodoco) as the first specific anti-inflammatory drug demonstrated to reduce the risk for myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.

The drug targets residual inflammation as an underlying cause of atherosclerotic cardiovascular disease, and can be used alone or in combination with cholesterol-lowering medications.

Among patients receiving statins, inflammation assessed by high-sensitivity C-reactive protein (hsCRP) was a stronger predictor for risk of future cardiovascular events and death than LDL-cholesterol.

[prophetoffactz]

So, if avenanthramides is believed to have a more favorable safety/tolerability profile than colchicine and this is supported by CZO's Phase I clinical trial which is expected to be completed by the end of this year this may largely leave efficacy risk. If Dr. Tardif can compelllingly compare the human biomarkers avenanthramide elicits to FDA appproved colchicine that could be favorable for

[prophetoffactz]

Entering a New Era of Patient Care: Reducing Inflammation: Reducing inflammation is now an FDA approved path for cardiovascular disease potentially validating the path for CZO's avenanthramide which may also help manage glucose levels for diabetics, and aid in wound healing, etc. "LODOCO can reduce the risk of cardiac events in patients with established cardiovascular diseases by 31% on